Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pulmicort
Asia
AZ expects slower growth for star China business
Over $1 billion in annual sales from older AstraZeneca drugs are being exposed to China's volume-based procurement, one analyst noted.
Angus Liu
Jul 29, 2021 12:05pm
BMS-Eisai, China price cuts, AZ-Hutchmed—Fierce Pharma Asia
Jun 25, 2021 10:50am
AZ's Pulmicort, Bayer's Xarelto among losers in China's VBP
Jun 24, 2021 11:38am
AstraZeneca, Novartis, Clover and more—FiercePharmaAsia
Nov 6, 2020 9:48am
Tagrisso, Imfinzi rescue AstraZeneca as Pulmicort drags in China
Nov 5, 2020 11:32am
Daiichi Sankyo, AstraZeneca, Fujifilm and more—FiercePharmaAsia
Jul 31, 2020 9:50am
